McWherter Charles — SEC Form 4 filings
SEC reporting owner CIK 1588862. 8 Form 4 filings on record with FilingPulse; latest filed 2025-10-30.
Transaction summary — filings shown
Covers all 8 filings on record, filed 2024-01-22 to 2025-10-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 2 filings — 25,000 shares, $179,850 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 5 legs across 1 filing — 18,403 shares, $435,645 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 30.
- Largest priced transaction: sale of 8,334 shares @ $23.68 ($197,316) in CymaBay Therapeutics, Inc., filed 2024-01-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| CymaBay Therapeutics, Inc. (CBAY) | President of R&D | 3 | — | 5 legs · 18,403 sh · $435,645 | 25 |
| 89bio, Inc. (ETNB) | Director | 5 | 3 legs · 25,000 sh · $179,850 | — | 5 |
Form 4 filings — McWherter Charles
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-10-30 | 4 | 89bio, Inc. (ETNB) | Code (U): 25,000 · Disposition to issuer (D): 67,700 (derivative) @ $0 · Disposition to issuer (D): 56,400 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 56,400 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | 89bio, Inc. (ETNB) | Purchase (P): 5,000 @ $6.55 · Purchase (P): 10,000 @ $6.71 | EDGAR |
| 2024-12-09 | 4 | 89bio, Inc. (ETNB) | Purchase (P): 10,000 @ $8 | EDGAR |
| 2024-08-07 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 67,700 (derivative) @ $0 | EDGAR |
| 2024-03-22 | 4 | CymaBay Therapeutics, Inc. (CBAY) | Disposition to issuer (D): 15,000 · Disposition to issuer (D): 31,938 · Disposition to issuer (D): 91,666 (derivative) · Disposition to issuer (D): 51,750 (derivative) · Disposition to issuer (D): 44,084 (derivative) · Disposition to issuer (D): 97,222 (derivative) · +7 more | EDGAR |
| 2024-01-26 | 4 | CymaBay Therapeutics, Inc. (CBAY) | Grant/award (A): 31,938 @ $0 · Grant/award (A): 118,625 (derivative) @ $0 | EDGAR |
| 2024-01-22 | 4 | CymaBay Therapeutics, Inc. (CBAY) | Option exercise (M): 2,250 @ $1.06 · Sale (S): 2,250 @ $23.67 · Option exercise (M): 2,778 @ $1.72 · Sale (S): 2,778 @ $23.66 · Option exercise (M): 1,916 @ $1.82 · Sale (S): 1,916 @ $23.66 · +9 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1588862 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →